Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study

被引：0

作者：

Ryusei Matsuyama

Daisuke Morioka

Ryutaro Mori

Seigo Hiratani

Yasuhiro Yabushita

Yohei Ota

Takafumi Kumamoto

Koichi Taniguchi

Itaru Endo

机构：

[1] Yokohama City University Graduate School of Medicine,Department of Gastroenterological Surgery

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 81卷

关键词：

Biliary tract cancer; Gemcitabine; Cisplatin; S-1; Refractory;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：949 / 955

页数：6

共 76 条

[61]

Paik YH(undefined)undefined undefined undefined undefined-undefined

[62]

Chang YS(undefined)undefined undefined undefined undefined-undefined

[63]

Riechelmann RP(undefined)undefined undefined undefined undefined-undefined

[64]

Townsley CA(undefined)undefined undefined undefined undefined-undefined

[65]

Chin SN(undefined)undefined undefined undefined undefined-undefined

[66]

Iqbal S(undefined)undefined undefined undefined undefined-undefined

[67]

Rankin C(undefined)undefined undefined undefined undefined-undefined

[68]

Lenz HJ(undefined)undefined undefined undefined undefined-undefined

[69]

Alberts SR(undefined)undefined undefined undefined undefined-undefined

[70]

Al-Khatib H(undefined)undefined undefined undefined undefined-undefined